MXCT (MaxCyte) Quality Rank


MXCT MaxCyte Inc MXCT
59 GF Score
Price $1.22
GF Value $2.57
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MaxCyte Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

MaxCyte Quality Rank Related Terms

MXCT
59GF Score
MaxCyte Inc MXCT
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MaxCyte (MXCT) Overvalued in 2026?

Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued. The current stock price of $1.22 is trading 52.7% below its estimated GF Value™ of $2.57. GuruFocus considers MaxCyte to be Possible Value Trap.

Key valuation signals for MXCT:

  • Quality Rank:
  • GF Value™: $2.57 vs. price of $1.22 (52.7% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MaxCyte Business Description

Other Exchanges MYE0:Germany
Address 9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
59GF Score

Get the complete analysis for MXCT

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.22
Price
$2.57
GF Value